Showing results (571-580 of 1,300) with videos related to

Sort By:
Pageof 130
JAMA Cardiology|August 4, 2016
Practice Patterns and Outcomes Associated With Use of Anticoagulation Among Patients With Atrial Fibrillation During SepsisAllan J Walkey, Emily K Quinn, Michael R Winter, et al.
JAMA Cardiology|September 8, 2021
Gender Differences in Medicare Payments Among CardiologistsInbar Raber, Mahmoud Al Rifai, Cian P McCarthy, et al.
JAMA Cardiology|September 15, 2021
Association of Myocardial Blood Flow Reserve With Adverse Left Ventricular Remodeling in Patients With Aortic Stenosis: The Microvascular Disease in Aortic Stenosis (MIDAS) StudyWunan Zhou, Yee-Ping Sun, Sanjay Divakaran, et al.
JAMA Cardiology|February 1, 2023
Quantifying and Interpreting the Prediction Accuracy of Models for the Time of a Cardiovascular Event-Moving Beyond C Statistic: A ReviewXuan Wang, Brian Lee Claggett, Lu Tian, et al.
JAMA Cardiology|February 1, 2023
Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical TrialBrett W Sperry, Mazen Hanna, Mathew S Maurer, et al.
JAMA Cardiology|February 1, 2023
Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart DiseaseJacqueline S Dron, Aniruddh P Patel, Yiyi Zhang, et al.
JAMA Cardiology|February 28, 2023
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO TrialsAjay J Kirtane, Andrew S P Sharp, Felix Mahfoud, et al.
JAMA Cardiology|November 9, 2022
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical TrialMichel Azizi, Felix Mahfoud, Michael A Weber, et al.
JAMA Cardiology|November 9, 2022
Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care NetworkAlexander J Blood, Christopher P Cannon, William J Gordon, et al.
JAMA Cardiology|December 10, 2025
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate ReductionPaul M Ridker, Florian M M Baeres, Anders Hveplund, et al.
Pageof 130